Correspondence  by unknown
a step closer to discovering the connection between these condi-
tions. Unfortunately, several methodologic limitations have re-
stricted interpretation of the data from the present study. Gasp-
ardone et al. use the method first proposed by Canessa et al.,
without making allowances for changes to assay methodology over
the past two decades. First, the issue of using magnesium in the
sodium-free media has not been addressed. This may have had
subtle effects on outcomes of SLC characterization (5,6). Second,
Gaspardone et al. fail to recognize the issue of distribution of SLC
activity within populations (1). Activity of SLC is not normally
distributed and as such should not be reported as a mean value 6
SD (4,5). Finally, determining activity as opposed to performing
kinetic characterization prevents the work of Gaspardone et al.
from being put into context with recent investigations into SLC
behavior. Kinetic investigations have confirmed the critical roles of
the maximal rate of turnover (Vmax) and external affinity constant
(km) in the relation between SLC behavior and various disease
processes (4,5). These two constants appear to represent two
distinct SLC characteristics operating under different influences.
In hypertension, km is altered—expressed in the form of a lower
km, possibly reflecting a higher affinity for external sodium that
may have a genetic basis (4,5). With regard to the broader issue of
vascular disease, there is evidence to suggest low km in patients
with coronary artery disease (7). In the case of diabetes, reduced km
occurs when the patient has nephropathy; however, Vmax is also
reduced (4,5). In contrast, patients with chronic diabetes with no
evidence of renal damage demonstrate elevated Vmax. Further-
more, Vmax is related to fluidity of the erythrocyte membrane (4,5).
This suggests that environmental factors such as plasma lipids may
be exerting effects on the countertransporter. Changes in SLC
behavior associated with diabetes may therefore relate to patho-
logic changes in lipid metabolism and membrane fluidity.
Gaspardone et al. make two controversial assumptions in their
work. First, in claiming to have determined Vmax using the method
of Canessa et al., Gaspardone et al. is incorrect (1). The method of
Canessa et al. measures a lithium efflux rate under highly specific
conditions that are not representative of the biochemical constant
Vmax (4,5). Second, in their interpretation of their findings,
Gaspardone et al. relate the abnormal SLC activity in their
patients with syndrome X to the expression of abnormal behavior
in the sodium–hydrogen exchanger (SHE) (1). We recognize that
similarities between these membrane transporters support the
hypothesis that SHE and SLC represent different functional
responses of a single membrane protein. However, it is well
accepted that there are several missing links that stand in the way
of the confirmation of this otherwise attractive theory, and we
caution against too ready acceptance (5,8). Furthermore, the
cluster of “dowels” that Gaspardone et al. suggest may be linked by
enhanced SHE activity, including coronary prearteriolar dysfunc-
tion, hyperinsulinemia and the predominance of sympathetic
activity, could equally be explained by defects in the cell membrane
itself. The membrane resident receptors, enzymes and transporters
that mediate many of these processes are sensitive to the compo-
sition of the cell membrane, and major changes in the properties of
the membrane can be imposed by minor alterations in lipid
composition (9). Such alterations could also explain the abnormal
SLC behavior noted in the study of Gaspardone et al. (1). The
aforementioned hypothesis does not require a specific error in the
coding of a single transporter and relates these observations more
to environmental rather than genetic factors.
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REPLY
Considerations by Hardman et al. about the recent identification
of a clearcut elevation of the maximal velocity (Vmax) of red blood
cell sodium–lithium countertransport (SLC) in patients with
cardiac syndrome X (1) are of interest. These authors state that the
identification of increased SLC activity in essential hypertension
(2) has not been confirmed by some subsequent studies, and they
conclude that it is not possible to predict hypertension on the basis
of the Vmax of SLC. We fully agree with these conclusions.
However, it needs to be clarified that our study was carried out in
a very select group of patients with cardiac rather than metabolic
syndrome X (3) who are by definition normotensive. Thus,
Hardman et al. seem to mistake cardiac for metabolic syndrome X.
Consequently, it is difficult for us to comment on the role of a
condition (i.e., hypertension) that was absent in our patients and
was an exclusion criterium for patient selection.
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With regard to essential hypertension, we agree that this is a
multifactorial condition. Obviously, all variables, including blood
pressure levels itself, cannot show clear cutoff differences between
normotensive and hypertensive patients, and there is no possibility
of identifying a marker of hypertension in the whole population.
As a consequence, neither an elevated Vmax of red blood cell SLC
nor any other variable can represent a marker of essential hyper-
tension. In contrast, this assumption is not true for the identifi-
cation of hypertensive patient subsets or hypertension sequelae,
which could both be influenced by major genes rather than
polygenes. With the use of the method by Canessa et al. (2) with
appropriate modifications, Redgrave et al. (4) and our group (5)
have clearly demonstrated the elevation of SLC activity in a subset
of patients with essential hypertension known as “nonmodulators.”
An elevated Vmax of red blood cell SLC predicted the blood
pressure responses to changes in sodium intake in salt-sensitive but
not salt-resistant subsets of patients with essential hypertension
(6,7). Nosadini et al. (8) clearly linked SLC hyperactivity to the
presence of hypertension-related target organ damage. Doria et al.
(9) showed a clear correlation between SLC hyperactivity and
insulin resistance in essential hypertension. The aforementioned
studies also showed the ability of elevated SLC activity to act as a
marker of familial hyperlipidemia or hypertension. Therefore,
there is a clear association among an elevated Vmax of red blood cell
SLC, hypertension subtypes and hypertension sequelae in hyper-
tensive patients and their families. Again, our study did not focus
on such associations because hypertensive patients were excluded.
A second observation made by Hardman et al. is related to the
well-known bimodal distribution of SLC in hypertensive patients
and hypertensive relatives. Again, we had no hypertensive patients
and hypertensive relatives among our patients and gender-matched
control subjects. Furthermore, in Figure 1 of our study, individual
data of SLC appear to be normally distributed.
Hardman et al. raised another interesting point regarding the
controversial assumption that SLC is an in vitro expression of the
behavior of the sodium–hydrogen exchanger. This subject is still a
matter of controversy. However, there has been great interest in
the recent report of Koren et al. (10), who observed an increased
activity of the sodium–hydrogen exchanger in a group of patients
with cardiac syndrome X.
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Angina Pectoris,
Myocardial Infarction and Verapamil
The excellent review of unstable angina (UA) and non–Q-wave
myocardial infarction by Zaacks et al. (1) contained a statement
that may mislead the reader: “The Multicenter Diltiazem Post
Infarct Trial found a significant reduction of adverse cardiac events
in patients receiving diltiazem who did not have pulmonary edema
on presentation. Similar favorable findings cannot be extrapolated
to include other calcium channel blockers such as verapamil . . ..”
Zaacks et al. do not include the results from the Danish Verapamil
Infarction Trial (DAVIT) II (2) in their review. The DAVIT II, a
double-blind, randomized, placebo-controlled postinfarct trial of ve-
rapamil (120 mg t.i.d.), which included 1,775 patients, demonstrated
a significant reduction in major events (i.e., first reinfarction or death
in verapamil-treated [18.0%] compared with placebo-treated patients
[21.6%]; hazard ratio [HR] 0.80, 95% confidence intervals [CI] 0.64
to 0.99). In an a priori–determined subgroup analysis, in relation to
treatment for congestive heart failure (CHF) before randomization, in
patients without CHF verapamil significantly prevented death (7.7%)
as compared with placebo (11.8%) (HR 0.64, 95% CI 0.44 to 0.94).
Also, the reinfarction rate was significantly lower in the verapamil
group (9.2% vs. 12.7%) (HR 0.67, 95% CI 0.46 to 0.97). No harm
was found in patients with CHF.
In a recent, small, double-blind postinfarct study of patients
with CHF being treated with the angiotensin-converting enzyme
inhibitor trandolapril, verapamil significantly prevented reinfarc-
tion, UA and CHF (3).
A post hoc analysis of DAVIT I demonstrated that verapamil
prevented the development of myocardial infarction in patients
admitted to the hospital with UA (4). Verapamil also prevented
post infarct angina (2,5). In conclusion, the statement of Zaacks et
al. should be changed to: “Verapamil also prevented death,
reinfarction and angina pectoris in postinfarct patients; the effect is
most pronounced in patients without CHF.”
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